1 / 1

MetroHealth Medical Center Outpatient Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin Catalyst In

MetroHealth Medical Center Outpatient Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin Catalyst Initiative Improvement Project. Improvement Cycles Required Development of a Patient Education Program Development of a standardized follow-up system in the outpatient setting

ostinmannual
Download Presentation

MetroHealth Medical Center Outpatient Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin Catalyst In

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. MetroHealth Medical Center Outpatient Treatment of Venous Thromboembolism with Low-Molecular-Weight Heparin Catalyst Initiative Improvement Project • Improvement Cycles Required • Development of a Patient Education Program • Development of a standardized follow-up system in the outpatient setting • Involvement of multiple health care disciplines • Resolution of cost issues • Conclusions / Results • Patients admitted to MHMC with VTE can be safely and effectively treated as outpatients with LMWH after a short hospital stay • Pre-ProtocolProtocol • Total patients 60 59 • Related re-admits 4 3 • Avg. Length of Stay 5.8 days 2.8 days • Average days on protocol = 8 days • Aim of Project • To provide safe outpatient management of patients with Venous Thromboembolism (VTE), including Deep Vein Thrombosis (DVT) and/or stable Pulmonary Embolism (PE), through the use of enoxaparin, a low-molecular-weight heparin (LMWH) which can be given by subcutaneous injection at home. • Background • Conventional treatment consisted of: • IV Heparin to prevent further clots • Frequent blood draws during hospital stay • LOS 5-7 days • Proposed treatment consisted of: • Injections given once or twice per day instead of IV Heparin • Blood draws once a day at home or clinic • Less time in hospital (LOS 1-2 days) • How did we overcome the Barriers? • Team developed pre-printed orders which included: • Inclusion, exclusion criteria • Weight-based LMWH dosing • Initial oral blood thinner dosing • Patient education materials • Discharge Planning Orders • Monitoring log • Information on Indigent Medication Assistance Program • Nursing and Physician Staffs were educated about the new protocol • Team Members • Marigel Constantiner (Team Leader) • Matt Eisen (Facilitator) • Sandie Amin (Facilitator) • Robert Bahler • Manoharan Balakrishnan • Teresa Drocton • Gaby El-Khoury • Linda Horvath • Cheryl Horvitz • Marcia Kucler • Kathy Lehman • Thomas Lukens • Margie Mazur • Greg Palmer • Lynette Seebohm CATALYST INITIATIVE Quality Resource Unit • Barriers • Increased drug cost (~ $300 for a 7 day supply) • Lack of insurance for drug coverage • Uninsured and underinsured patients • Lack of reimbursement for Home Care • Lack of routine retail pharmacy stocking

More Related